Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner - - Three INDs for wholly ...
Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition - - Cash, cash equivalents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback